/
and Mission Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights.
The business is unprofitable at the operating level (-46.96% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 1.6% YoY. Margins deteriorated 32.2pp alongside, both lines moving the wrong way.
ROIC dropped from -10.98% to -43.11%, capital efficiency is deteriorating. Operating margin contracted 32.2pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$829M
▼ -1.6% YoY
Net Income (TTM)
-$400M
▼ -187.4% YoY
Op. Margin
-46.91%
▼ -32.2pp YoY
ROIC
-54.51%
▼ -32.1pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$2M
▲ +120.7% YoY
Net Debt
$87M
Cash & Equiv.
$124M
5Y CAGR: +8.2%
Continue Research